Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aliraza Jaffer

Pain Medicine Troy, MI Medical Doctor

NPI 1699744185 CMS profile 167236

1560 E Maple Rd Ste 290, Troy, MI 48083

Open in the dashboard

General payments

$11,783

167 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aliraza Jaffer of Troy, MI is reported in the CMS Open Payments database as having received $11,783 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,518 50
2024 General $4,930 73
2023 General $2,387 29
2022 General $411 6
2021 General $312 7
2019 General $225 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aliraza Jaffer
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Aliraza Jaffer were reported at $3,518. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Aliraza Jaffer Pain Medicine median Middle half National median
2019 $225 $506 $144–$1,566 $163
2020 $0 $315 $96–$934 $114
2021 $312 $452 $134–$1,237 $132
2022 $411 $475 $124–$1,407 $149
2023 $2,387 $480 $136–$1,384 $160
2024 $4,930 $521 $164–$1,511 $164
2025 $3,518 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,813 50 payments
  2. Nevro Corp. $2,784 43 payments
  3. Globus Medical, Inc. $1,207 20 payments
  4. SI-BONE, Inc. $1,132 8 payments
  5. Boston Scientific Corporation $1,011 25 payments
  6. Medtronic, Inc. $871 10 payments
  7. SPR Therapeutics, Inc $328 4 payments
  8. MML US, Inc. $265 2 payments
  9. Pacira Pharmaceuticals Incorporated $122 1 payment
  10. ConvaTec Inc. $114 1 payment
  11. Other $135 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,319 153 payments
  2. Travel and Lodging $2,111 12 payments
  3. Education $352 2 payments
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulator $2,022 29 payments
  2. PROCLAIM Neuromodulation $1,301 18 payments
  3. Senza Spinal Cord Stimulator $1,207 20 payments
  4. IFUSE IMPLANT SYSTEM $892 5 payments
  5. PROCLAIM Neuromodulation $884 10 payments
  6. PROCLAIM Neuromodulation $673 5 payments
  7. WaveWriter Alpha Prime 16 $651 20 payments
  8. Omnia $570 11 payments
  9. INTELLIS ADAPTIVESTIM $350 6 payments
  10. SPRINT PNS System $328 4 payments
  11. Other $2,489 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$123,649

Of which drugs: $456

Medicare patients

228

Average age 76

Services billed

8,030

136 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Diabetes 33%
Chronic kidney disease 28%
Depression 25%
Cancer 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 146 2,557 $227
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 125 517 $148
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 78 3,701 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record